ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Abiraterone Acetate

Also written as “Abiraterone acetate”, “Abiraterone” and “abiraterone acetate”.

Its studies are mostly in Prostatic Neoplasms · Neoplasm Metastasis · Breast Neoplasms · Bulbo-Spinal Atrophy, X-Linked · Prostatic Neoplasms, Castration-Resistant, led by 8 companies.

Drug pageAbiraterone Acetate: every studyMany companies study it; this page follows only the 53 they lead. All 127 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 27, 201553 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson414 open or runningphase 4since Mar 27, 2015May 11, 2007none ahead
Jiangsu HengRui Medicineits history only32 open or runningphase 2since Apr 25, 2021Apr 25, 2021Dec 2026phase 2 · NCT06568094
Sun Pharmaceutical Industriesits history only31 open or runningphase 2since Mar 25, 2016Mar 25, 2016Dec 31, 2027phase 2 · NCT05422911
Sanofiits history only20 open or runningphase 4since Jun 26, 2015Jan 4, 2012none ahead
Boryung Pharmaceuticalits history only10 open or runningphase 1since May 12, 2021May 12, 2021none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 3since Aug 11, 2019Aug 11, 2019none ahead
Sumitomo Pharmaits history only10 open or runningphase 1since Dec 7, 2020Dec 7, 2020none ahead
Zentiva, k.s.its history only10 open or runningphase 1since Mar 2, 2020Mar 2, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 26 studies since May 11, 2007.

  1. Sep 25, 2012Phase 3 study in Prostatic NeoplasmsNCT01695135 · 214 enrolled · China
  2. Oct 22, 20122 phase 1 studiesNCT01798628, NCT01715259
  3. Oct 24, 2012Phase 3 study in Prostatic NeoplasmsNCT01715285 · 1,209 enrolled · Argentina, Australia, Belgium and more
  4. Dec 20, 2012Phase 2 study in Prostatic NeoplasmsNCT01756638 · 48 enrolled · Japan
  5. Jan 30, 2013Phase 2 study in Prostatic NeoplasmsNCT01795703 · 47 enrolled · Japan
  6. Jun 5, 2013Phase 1 study in Healthy VolunteersNCT01873001 · 16 enrolled · Belgium
  7. Oct 31, 2013Phase 1 study in Prostatic NeoplasmsNCT02001571 · 24 enrolled · United States
  8. Apr 21, 2014Phase 1 study in Prostatic NeoplasmsNCT02123758 · 57 enrolled · United States, Canada, Netherlands and more
  9. Aug 13, 2014Phase 2 study in Prostatic NeoplasmsNCT02217566 · 46 enrolled · Brazil
  10. Aug 29, 2014Phase 1 study in HealthyNCT02230046 · 102 enrolled · United States
  11. Mar 27, 2015Phase 4 study in Metastatic Castration-Resistant Prostate CancerNCT02405858 · 51 enrolled · Japan
  12. Nov 19, 2018Phase 3 study in Prostatic Neoplasms, Castration-ResistantNCT03748641 · 765 enrolled · United States, Argentina, Australia and more
  13. Jul 31, 2020Phase 3 study in Prostatic NeoplasmsNCT04497844 · 696 enrolled · United States, Argentina, Australia and more
  14. Oct 5, 2020Phase 1 study in Prostatic NeoplasmsNCT04577833 · 136 enrolled · United States, Belgium, France and more

TargetBeta

CYP17A1 →read by rule
“Cytochrome P450 17A1 inhibitor”ChEMBL 37, by rule

Studies

All 41 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04577833Prostatic Neoplasms · United States, Belgium, France and more1Active, not recruitingOct 15, 2021136
NCT04497844Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJan 7, 2025696
NCT03748641Prostatic Neoplasms, Castration-Resistant · United States, Argentina, Australia and more3Active, not recruitingOct 8, 2021765
NCT02405858Metastatic Castration-Resistant Prostate Cancer · Japan4CompletedDec 31, 201751
NCT02230046Healthy · United States1CompletedNov 2014102
NCT02217566Prostatic Neoplasms · Brazil2CompletedOct 26, 201846
NCT02123758Prostatic Neoplasms · United States, Canada, Netherlands and more1Active, not recruitingJun 27, 201657
NCT02001571Prostatic Neoplasms · United States1CompletedApr 201024
NCT01873001Healthy Volunteers · Belgium1CompletedJul 201316
NCT01795703Prostatic Neoplasms · Japan2CompletedOct 201447
NCT01756638Prostatic Neoplasms · Japan2CompletedOct 17, 201448
NCT01715285Prostatic Neoplasms · Argentina, Australia, Belgium and more3CompletedOct 31, 20161,209
NCT01715259Renal Insufficiency · United States1CompletedJan 201016
NCT01798628Healthy Volunteers1CompletedOct 200936
NCT01695135Prostatic Neoplasms · China3CompletedJun 20, 2014214
NCT01685983Prostatic Neoplasms · Korea, Republic of, Taiwan2CompletedJan 24, 201382
NCT01678573Healthy · China1CompletedSep 201215
NCT01664728Prostatic Neoplasms · United Kingdom1CompletedFeb 200954
NCT01640093Healthy Participants · United States1CompletedJul 201232
NCT01591122Prostatic Neoplasms · China, Malaysia, Russian Federation and more3CompletedDec 31, 2016313
NCT01655147Healthy · Belgium1CompletedMar 201219
NCT01517802Breast Neoplasms · United States, Australia, Belgium and more3CompletedApr 22, 202132
NCT01575587Pharmacology · United States1CompletedMay 201251
NCT01588782Healthy Volunteers · Belgium1CompletedFeb 201220
NCT01495910Congenital adrenal hyperplasia due to 21 hydroxylase deficiency · United States1CompletedFeb 20136
NCT01424930Prostatic Neoplasms · Canada2CompletedApr 201325
NCT01381874Breast Neoplasms · United States, Belgium, France and more2CompletedJul 28, 2014297
NCT01362764Healthy Volunteers1CompletedJun 201130
NCT01314118Prostatic Neoplasms · United States2CompletedDec 24, 2013131
NCT01186484Prostatic Neoplasms · Japan1CompletedOct 2, 201427
NCT01017939Prostatic Neoplasms · United States, Canada1CompletedJun 201034
NCT00924469Prostatic Neoplasms · United States2CompletedFeb 201258
NCT00910754Prostatic Neoplasms · United States, Canada1CompletedNov 200933
NCT00887198Prostatic Neoplasms · United States, Australia, Belgium and more3CompletedMar 31, 20141,088
NCT00638690Prostatic Neoplasms · United States, Australia, Austria and more3CompletedAug 20101,195
NCT00600535Prostatic Neoplasms · United States, United Kingdom1CompletedMar 201231
NCT00544440Prostatic Neoplasms · United States2CompletedAug 201257
NCT00485303Prostatic Neoplasms · United States, United Kingdom2CompletedOct 201158
NCT00474383Prostatic Neoplasms · United States, United Kingdom2CompletedAug 201147
NCT00473746Prostatic Neoplasms · United States2CompletedDec 201266
NCT00473512Prostatic Neoplasms · United Kingdom2CompletedNov 200854

How it is read

Names in the registry

  • “Abiraterone acetate”, 24 entries
  • “Abiraterone”, 10 entries
  • “Abiraterone Acetate”, 5 entries
  • “abiraterone acetate”, 2 entries
  • “Abiraterone acetate (Treatment B)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.